China Biologic Products to Report Second Quarter of 2017 Financial Results

China Biologic Products, Inc. (NASDAQ: CBPO) ("China Biologic" or the "Company"), a leading fully integrated plasma-based biopharmaceutical company in China, today announced that the Company plans to release second quarter of 2017 financial results on Wednesday, August 2, 2017 after the market closes.

The Company's management will hold a conference call at 7:30 a.m. ET on Thursday, August 3, 2017, which is 7:30 p.m., Beijing Time on August 3, 2017, to discuss second quarter of 2017 results. Listeners may access the call by dialing:

US:                                                      1 888 346 8982

International:                                       1 412 902 4272          

Hong Kong, S.A.R., China:                                         800 905 945   

China:                                                  400 120 1203

A telephone replay will be available one hour after the conclusion of the conference call through August 10, 2017. The dial-in details are:

US:                                                      1 877 344 7529

International:                                       1 412 317 0088          

Passcode:                                           10110775

About China Biologic Products, Inc.

China Biologic is a leading plasma-based biopharmaceutical company in China. The Company's products are used as critical therapies during medical emergencies and for the prevention and treatment of life-threatening diseases and immune-deficiency related diseases. China Biologic is headquartered in Beijing and manufactures over 20 different dosages of plasma-based products through its majority-owned subsidiary, Shandong Taibang Biological Products Co., Ltd., and its wholly-owned subsidiary, Guizhou Taibang Biological Products Co., Ltd. The Company also has an equity investment in Xi'an Huitian Blood Products Co., Ltd. The Company sells its products to hospitals and inoculation centers, as well as distributors, in China.